Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of ...

Pfizer has caught investors’ eyes recently, outperforming its peers slightly but facing modest growth prospects ahead.

Tuesday: JPMorgan Chase, Wells Fargo, Citigroup, BlackRock, and Bank of New York Mellon release results. Wednesday: Bank of ...

Pfizer (PFE) ended the recent trading session at $25.35, demonstrating a -1.17% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14%.

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Analysts estimate that Albertsons Companies will report an earnings per share (EPS) of $0.52. Investors in Albertsons ...

Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company ...

On a per-share basis, the New York-based company said it had profit of 52 cents. Earnings, adjusted for amortization costs and restructuring costs, were 92 cents per share.

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings tomorrow before market hours. Here’s what you need to know.

Pfizer (NYSE:PFE – Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Tuesday, April 29th. Analysts expect Pfizer to post earnings of $0.67 ...

Pfizer’s PFE 2024 revenue reached $63.6 billion, near the high end of its $61 billion-$64 billion guidance range. Management reaffirmed expectations for 2025 revenue of $61 billion-$64 billion ...

Pfizer (PFE) is set to announce Q3 earnings with analysts predicting strong profit and revenue growth.